Business Wire·Oct 14, 2025, 12:00 PM ET

Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI

Frontier AI company Albert Invent & Kenvue Inc. announced a strategic partnership to accelerate end-to-end R&D efforts across Kenvue's global brand portfolio.
The multi-year collaboration began in Q1 2025 to streamline, digitalize, & accelerate product lifecycles using Albert Invent's foundational AI models.
The partnership aims to augment Kenvue's global scientists by integrating AI into daily workflows to gain efficiencies inside & outside the lab.
Albert Invent utilizes a proprietary AI engine trained on over 15 million molecular structures to design safer, higher-performing products at unprecedented speed.
The platform unifies data management, digitalizes workflows, & automates processes to eliminate silos, enhance transparency, & strengthen regulatory compliance.
Kenvue plans to use this technology to reinvent consumer health by connecting decades of research with AI-powered data capabilities.
Kenvue is the world's largest pure-play consumer health company with iconic brands including Zyrtec, Neutrogena, Listerine, Aveeno, BAND-AID, Johnson's, & Tylenol.
Albert Invent is based in Oakland, California, & serves thousands of researchers in more than 30 countries with backing from investors like J.P. Morgan Private Capital & Coatue.
The press release includes forward-looking statements regarding a five-year collaboration & warns that actual results may vary due to risks & uncertainties.